1542 related articles for article (PubMed ID: 23940285)
1. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening.
Feig S
Radiol Clin North Am; 2010 Sep; 48(5):879-91. PubMed ID: 20868891
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
Saadatmand S; Obdeijn IM; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Woldringh GH; Bergers E; Verhoef C; Heijnsdijk EA; Hooning MJ; de Koning HJ; Tilanus-Linthorst MM
Int J Cancer; 2015 Oct; 137(7):1729-38. PubMed ID: 25820931
[TBL] [Abstract][Full Text] [Related]
7. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
[TBL] [Abstract][Full Text] [Related]
9. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
[TBL] [Abstract][Full Text] [Related]
12. Comparison of costs and benefits of breast cancer screening with mammography, ultrasonography, and MRI.
Feig S
Obstet Gynecol Clin North Am; 2011 Mar; 38(1):179-96, ix. PubMed ID: 21419333
[TBL] [Abstract][Full Text] [Related]
13. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk.
Podo F; Sardanelli F; Canese R; D'Agnolo G; Natali PG; Crecco M; Grandinetti ML; Musumeci R; Trecate G; Bergonzi S; De Simone T; Costa C; Pasini B; Manuokian S; Spatti GB; Vergnaghi D; Morassut S; Boiocchi M; Dolcetti R; Viel A; De Giacomi C; Veronesi A; Coran F; Silingardi V; Turchett D; Cortesi L; De Santis M; Federico M; Romagnoli R; Ferrari S; Bevilacqua G; Bartolozzi C; Caligo MA; Cilotti A; Marini C; Cirillo S; Marra V; Martincich L; Contegiacomo A; Pensabene M; Capuano I; Burgazzi GB; Petrillo A; Bonomo L; Carriero A; Mariani-Costantini R; Battista P; Cama A; Palca G; Di Maggio C; D'Andrea E; Bazzocchi M; Francescutti GE; Zuiani C; Londero V; Zunnui I; Gustavino C; Centurioni MG; Iozzelli A; Panizza P; Del Maschio A
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):115-24. PubMed ID: 12585665
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.
Sankatsing VD; Heijnsdijk EA; van Luijt PA; van Ravesteyn NT; Fracheboud J; de Koning HJ
Int J Cancer; 2015 Oct; 137(8):1990-9. PubMed ID: 25895135
[TBL] [Abstract][Full Text] [Related]
15. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Kriege M; Brekelmans CT; Boetes C; Muller SH; Zonderland HM; Obdeijn IM; Manoliu RA; Kok T; Rutgers EJ; de Koning HJ; Klijn JG;
Cancer; 2006 Jun; 106(11):2318-26. PubMed ID: 16615112
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
Rijnsburger AJ; Obdeijn IM; Kaas R; Tilanus-Linthorst MM; Boetes C; Loo CE; Wasser MN; Bergers E; Kok T; Muller SH; Peterse H; Tollenaar RA; Hoogerbrugge N; Meijer S; Bartels CC; Seynaeve C; Hooning MJ; Kriege M; Schmitz PI; Oosterwijk JC; de Koning HJ; Rutgers EJ; Klijn JG
J Clin Oncol; 2010 Dec; 28(36):5265-73. PubMed ID: 21079137
[TBL] [Abstract][Full Text] [Related]
17. MRI screening in a clinic population with a family history of breast cancer.
Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
[TBL] [Abstract][Full Text] [Related]
18. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
